Pierre Benite

• A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult P … Recruiting
  2023-505479-56-00 1 2025-07-30 Follicular lymphoma (FL)
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• BreAK CRC (001) trial Recruiting
  2024-512011-45-00 7 2025-06-17 Unresectable locally advanced or metastatic colorectal cancer
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn' … Recruiting
  2024-513054-30-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML … Recruiting
  2024-512733-32-00 5 2025-03-31 Acute Myeloid Leukemia (AML)
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor
• Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting
  2024-513219-29-00 5 2024-10-21 Renal Cell Carcinoma
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 Melanoma
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma
• Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Recruiting
  2023-507528-21-00 5 2024-05-23 Gorlin Syndrome
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 4 2024-04-08 Mantle Cell Lymphoma (MCL)
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting
  2024-513185-19-00 9 2022-07-13 Extensive stage small cell lung cancer (ES-SCLC)
• A Phase 1/2 Study of Bleximenib in Participants with Acute Leukemia Recruiting
  2023-506581-31-00 1 2021-06-15 Acute Leukemia
• A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Recruiting
  2023-510509-17-00 7 2020-06-17 Relapsed and/or refractory Acute Myeloid Leukemia
• NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The … Recruiting
  2022-500966-82-00 5 2020-03-11 Resectable locally advanced squamous cell carcinoma (SCC) of the esoph
• A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso … Recruiting
  2024-511855-16-00 5 2019-07-25 Onco-hematology
• AMAZE 1: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight Recruiting
  2024-520440-42-00 5 2026-05-07 Obesity
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity

Showing 73–96 of 404 trials